PF-04880594 NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: PF-04880594 | CAS No.: 1111636-35-1 |
| Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | PF-04880594 |
| Description | PF-04880594 is a potent and selective RAF inhibitor targeting both wild-type and mutant BRAF and CRAF, exhibiting antitumor activity [1]. |
| In vitro | PF-04880594 (100 nM, 48 h) causes ERK activation and stimulation of IL-8 release, both blocked by the treatment of PD-0325901 [1]. Western Blot Analysis [1] Cell Line: HL-60 Concentration: 100 nM alone or in combination with 100 nM PD-0325901 Incubation Time: 48 h Result: Induced ERK phosphorylation and induced IL-8 production. PD-0325901 treatment blocked the induction. |
| In vivo | PF-04880594, administered at 10 mg/kg, was observed to induce ERK phosphorylation and BRAF-CRAF dimerization across multiple epithelial tissues in mice, with the effects being mitigable by co-treatment with PD0325901. Additionally, when administered at doses ranging from 0-40 mg/kg twice daily over three weeks, PF-04880594 led to epithelial hyperplasia in mice, a condition that was effectively prevented by PD0325901. In experiments involving nude mice, a single day’s administration of 10 mg/kg PF-04880594, followed by a dose 2 hours before necropsy on the next day, resulted in ERK phosphorylation within urinary bladder, tongue, skin, and esophagus tissues, which was attenuated by a concurrent administration of 0.5 mg/kg PD0325901. Continuous administration of PF-04880594, at dosages of 10, 20, and 40 mg/kg in combination with varying doses of PD-0325901 (0.1, 0.3, 0.5, 1.0, or 2.5 mg/kg) for three weeks, highlighted microscopic pathologies typical of unopposed BRAF inhibition and reported that hyperplasia in nonglandular stomach epithelium could be obstructed by PD0325901. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | PF04880594 | PF 04880594 | PF-04880594 |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-20 | |
| $5.00/25kg |
VIP6Y
|
Jinan Finer Chemical Co., Ltd
|
2022-05-06 | |
| $2.00/1kg |
VIP2Y
|
Jinan Million Pharmaceutical Co., Ltd
|
2023-08-11 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY